Camptothecin induces differentiation, tissue transglutaminase and apoptosis in cultured keratinocytes

Experimental Dermatology

Volumn 7, Issue 4, 1998, Pages 179-183

  Lin, Xi Ran ^a   Wilkinson, David I ^b   Farber, Eugene M ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b Psoriasis Research Institute   (United States)

Author keywords

Apoptosis; Camptothecin; Differentiation; Keratinocyte; Transglutaminase

Indexed keywords

CAMPTOTHECIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; HUMAN; HUMAN CELL; KERATINOCYTE; PSORIASIS; TREATMENT INDICATION;

EID: 0031706064     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0625.1998.tb00321.x     Document Type: Article

References (39)

1. Wall M E, Wani M C, Cook C E. Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966: 83: 3888-3890.
2. Gottlieb J A, Guarino A M, Call J B, Oliverio V T, Block J B. Preliminary pharmacological and clinical evaluation of camptothecin (NSC 500880). Correlation with clinical studies. Cancer Chemother Rep 1970: 54: 461-470.
3. Muggia F M, Creaven P J, Hansen H H, Cohen M H, Selawry O S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880). Correlation with clinical studies. Cancer Chemother Rep 1972: 56: 515-521.
4. Chabner B A. Camptothecins (Editorial). J Clin Oncol 1992: 10: 3-4.
5. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 1994: 54: 1431-1439.
6. Horwitz S B, Chang C-K, Grollman A P. Studies on camptothecin. 1. Effect on nucleic acid and protein synthesis. Mol Pharmacol 1971: 17: 632-644.
7. Hsiang Y-H, Hertzberg R, Hecht S, Liu L F. Camptothecin induced protein linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-14878.
8. Hsiang Y-H, Liu L F. Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988: 48: 1722-1726.
9. Covey J M, Jaxel C, Kohn K W. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 1989: 49: 5016-5022.
10. Bertrand R. Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors. Exp Cell Res 1993: 207: 388-397.
11. Kaufman W K, Boyer J C, Estabrooks L L. Inhibition of replicon in human cells following stabilization of topoisomerase-DNA cleavable complexes. Mol Cell Biol 1991: 11: 3711-3718.
12. Bendixen C, Thomsen B, Alsner J, Westergaard O. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochem 1990: 29: 5613-5619.
13. Nakaya K, Chou S, Kaneko M, Nakamura Y. Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells. Jap J Cancer Res 1991: 82: 184-191.
14. Arends M J, Wyllie A H. Apoptosis: mechanisms and roles in pathology. Inter Rev Exp Pathol 1991: 32: 223-254.
15. Haake A R, Polakowska R R. Cell death by apoptosis in epidermal biology. J Invest Dermatol 1993: 101: 107-112.
16. McCall C A, Cohen J J. Programmed cell death in terminally differentiating keratinocytes: role of endogenous endonuclease. J Invest Dermatol 1991: 97: 111-114.
17. Wyllie A H. Apoptosis: cell death in tissue regulation. J Pathol 1987: 153: 313-316.
18. Piacentini M, Autuori F, Dini L et al. Tissue transglutaminase is specifically expressed in neonatal rat liver cells undergoing apoptosis upon epidermal growth factor stimulation. Cell Tissue Res 1991: 263: 227-235.
19. Fesus L, Davies P J A, Piacentini M. Apoptosis: molecular mechanisms in programmed cell death. Eur J Cell Biol 1991: 56: 170-177.
20. Fesus L, Thomazy V, Falus A. Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett 1987: 224: 104-108.
21. Del Bino G, Bruno S, Yi P N, Darzynkiewicz Z. Apoptotic cell death triggered by camptothecin or teniposide: the cell specificity and effects of ionizing radiation. Cell Prolif 1992: 25: 537-548.
22. Bruno S. Apoptosis of rat thymocytes by prednisolone. camptothecin or temposide is selective to Go cells and is prevented by inhibitors of proteases. Oncol Res 1992: 4: 29-35.
23. Williams G T. Programmed cell death: apoptosis and oncogenesis. Cell 1991: 65: 1097-1098.
24. Lin X-R, Huang T, Yang C-M, Cai-xia T, Guo-ling Y. Clinical trial and experimental study on treating psoriasis with camptothecin. Chin Med J 1988: 101: 427-430.
25. Haake A R, Graf B A, Polakawska R R. Bcl-2 down-regulation is not required for keratinocytic differentiation. J Invest Dermatol 1995: 104: 527 (abs).
26. Bohr V A, Abel E A, Farber E M, Hanawalt P C. Topical treatment of psoriasis with the topoisomerase inhibitor novobiocin and nalidixic acid: a pilot study. Arch Dermatol Res 1987: 279: 147-150.
27. Lin X-R. Huang T. Topical camptothecin in treatment of psoriasis. Int J Dermatol 1988: 27: 475-476.
28. Bina-Stein M, Tritton T M. Aurintricarboxylic acid in a non-specific enzyme inhibitor. Mol Pharmacol 1975: 12: 191-193.
29. Batistatou A, Greene L A. Aurintricarboxylic acid rescues PC-12 cells and sympathetic neurons from cell death caused by nerve growth factor deprivation: correlation with suppression of endonuclease activity. J Cell Biol 1991: 115: 461-471.
30. Liu S C, Karasek M. Isolation and growth of adult human epidermal keratinocytes in cell culture. J Invest Dermatol 1978: 71: 157-162.
31. Lichti U, Ben T, Yuspa S H. Retinoic acid-induced transglutaminase in mouse epidermal cells is distinct from epidermal transglutaminase. J Biol Chem 1985: 260: 1422-1426.
32. Paus R, Rosenbach T, Haas N, Czarnetzki B M. Patterns of cell death: the significance of apoptosis for dermatology. Exp Dermatol 1993: 2: 3-11.
33. Thacher S M, Rice R H. Keratinocyte-specific transglutaminase of cultured human epidermal cells: relation to cross-linked envelope formation and terminal differentiation. Cell 1985: 40: 685-694.
34. Suto N, Ikura K, Sasaki R. Expression induced by interleukin 6 of tissue-type transglutaminase in human hepato-blastoma HepG2 cells. J Biol Chem 1993: 268: 7469-7473.
35. Bianchi L, Farrace M G, Nini G, Piacentini M. Abnormal bcl-2 and "tissue" transglutaminase expression in psoriatic skin. J Invest Dermatol 1994: 103: 829-833.
36. Wrone-Smith T, Johnson T, Nelson B et al. Discordant expression of bcl-x and bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 1995: 146: 1079-1088.
37. Schopf R E, Welke F, Dobmeyer T, Dobmeyer J, Morsches B. Apoptosis of epidermal cells in psoriatic plaques is decreased. J Invest Dermatol 1995: 104: 610 (abs).
38. Prens E P, Benne K., van Damme J et al. Interleukin 1 and interleukin 6 in psoriasis. J Invest Dermatol 1990: 95: 121S-124S.
39. Heenen M, Laporte M, Noel J C, De Graef C. Low dose of methotrexate induces apoptotic cell death in human keratinocytes. J Invest Dermatol 1996: 106: 944 (abs).